Erasca Q3 loss widens as R&D spending rises

By Reuters News


Overview

  • US precision oncology firm's Q3 net loss widened yr/yr as R&D spending increased

  • Company ended Q3 with $948 mln in cash, up from $342 mln at 2025 year-end

  • Erasca received FDA Fast Track Designation for ERAS-0015 in metastatic pancreatic cancer


Outlook

  • Erasca expects preliminary Phase 1 monotherapy data for ERAS-4001 in H2 2026

  • Erasca expects Phase 1 monotherapy expansion data for ERAS-0015 in H1 2027

  • Company expects to initiate a Phase 3 pivotal trial in first line PDAC in 2027


Result Drivers

  • R&D SPENDING - Higher research and development expenses driven by increased clinical trials, preclinical studies, and personnel costs

  • FDA FAST TRACK - ERAS-0015 received FDA Fast Track Designation for metastatic pancreatic cancer, enabling more frequent FDA interactions as the program advances


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Loss Per Basic Share

$0.15


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for Erasca, Inc. is $22.00, about 31% above its November 11 closing price of $16.80


Reuters Recommended Reads

  • Nov 12 - 4D Molecular Therapeutics Q3 net loss widens on higher costs

  • Nov 12 - SELLAS Life Sciences Q3 net loss widens on higher R&D costs

  • Nov 12 - Kodiak Sciences Q3 net loss widens as R&D expenses rise


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk